Skip to main content
editorial
. 2011 Oct 27;3(10):265–267. doi: 10.4254/wjh.v3.i10.265

Table 1.

Effects of ezetimibe, alone or combined with other drugs, in non-alcoholic fatty liver disease-related variables in humans

Drug (s) Parameter
Ezetimibe[16] ↓Visceral fat area
↓HOMA
↓Triglycerides, ↓total cholesterol, ↓LDL-C
↓ALT
↓hsCRP
↓Steatosis grade and NAFLD activity score
Ezetimibe plus weight loss[17] ↓Intrahepatic triglyceride content
↓hsCRP
↓Interleukin-6
↓LDL-C
Ezetimibe plus orlistat[20-22] ↓Body mass index and waist circumference
↓Total cholesterol and triglycerides
↓HOMA
↓ALT, AST, γGT

NAFLD: Non-alcoholic fatty liver disease; HOMA: Homeostasis model assessment; LDL-C: Low density lipoprotein cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: γ-glutamyl-transpeptidase; hsCRP: High sensitivity C-reactive protein.